29 Aug 2025 Amendments to the Convertible Bond and equity fundraise of £3.25 million Investors | Therapeutics
30 Jul 2025 Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress Therapeutics
02 Jul 2025 Avacta Provides Q2 2025 Business Update Outlining Progress Against Strategic Objectives Investors
01 Jul 2025 Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development Investors | Therapeutics